DapaRizin 5mg (Dapagliflozin Monohydrate)
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
Kooju Pharmaceutical Co., Ltd.
MFDS item code 202005379 · Approved 2020.07.23
This product's status changed to Expired on 2025.07.23. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used as an adjunct therapy to assist in blood sugar control for patients with type 2 diabetes. It can be used alone or in combination with other medications, and it is important to accompany this treatment with diet and exercise. It is especially used for patients with cardiovascular disease or risk factors among those who do not have sufficient blood sugar control. It is advisable to review the clinical trial information from experts before use. This medication improves blood sugar management in type 2 diabetes.
Type 2 diabetes mellitus Monotherapy and add-on combination therapy The recommended dose of this medicine is 10mg once daily for monotherapy and add-on combination therapy with other glucose-lowering agents, such as insulin. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. Initial combination therapy For patients with no prior experience of antidiabetic drug therapy, when administered in combination with metformin, the recommended initial dose of this medicine is 5mg once daily or 10mg once daily. Special populations Renal impairment - eGFR less than 45 mL/min/1.73m2: Use of this medicine is not recommended for the purpose of improving glycemic control. - Patients on dialysis: Do not administer this medicine. Hepatic impairment No dose adjustment is required in patients with mild or moderate hepatic impairment. For patients with severe hepatic impairment, an initial dose of 5 mg is recommended. If well tolerated, this dose may be increased to 10mg. Elderly patients (≥ 65 years) Dose adjustment based on age is not recommended. Method of administration This medicine may be taken orally once daily at any time of day, with or without food. The tablet should be swallowed whole.
Pediatric patients The efficacy and safety of dapagliflozin in pediatric patients under 18 years of age have not been established. No relevant data are available.
This medication should not be used in patients who have had allergic reactions to the active ingredient or excipients. It should also not be administered to patients with type 1 diabetes or diabetic ketoacidosis. Patients with genetic disorders that prevent lactose breakdown should avoid this medication, as the included anhydrous lactose may cause problems. This medication is not administered to patients undergoing dialysis. This medication should be used cautiously in patients who have reduced fluid volume or kidney function issues. It may lower blood pressure and reduce blood volume, which can lead to symptomatic hypotension or kidney function deterioration. Patients with impaired kidney function, elderly patients, and those on diuretics are at greater risk, and their conditions should be closely monitored before and after administration. Caution is also necessary for patients with allergies to specific pigment components. During treatment, genital infections or urinary tract infections may occur, so immediate treatment is necessary if any infection symptoms arise. Symptoms of hypoglycemia may appear, especially when taken with insulin or sulfonylureas, so dosage adjustment may be necessary. Dehydration symptoms, dry mouth, and dizziness due to reduced fluid volume may occur, so adequate hydration and monitoring of symptoms are important. Severe metabolic instability known as diabetic ketoacidosis may rarely occur, so if symptoms such as abdominal pain, vomiting, or shortness of breath occur, immediate consultation with healthcare professionals is required. Regular kidney function tests are necessary as this medication may affect kidney function, and there may be an increase in creatinine levels. Rare but serious side effects, such as severe perineal necrosis (Fournier's gangrene), have been reported; if pain, swelling, or redness occurs around the genital area, inform a physician immediately. Women who are pregnant or nursing are advised against using this medication. This medication may increase the risk of hypoglycemia when used with other blood sugar-lowering agents; interactions with other medications being taken must be confirmed. There is no specific antidote for overdose; it is crucial to seek symptomatic treatment, and appropriate measures should be taken based on health status. Caution should be observed while driving or operating machinery during the course of this medication, especially in combination with insulin or sulfonylureas, due to the risk of hypoglycemia. Store this medication out of reach of children, and keep it in its original container to maintain quality.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container to prevent exposure to air or moisture, and it is advisable to keep it at room temperature between 1°C and 30°C. This storage helps maintain the medication's effectiveness over time.
Yellow, double convex, round film-coated tablet
28 tablets/box [(7 tablets/PTP x 4, 14 tablets/PTP x 2)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
Kooju Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
International Pharmaceuticals Co., Ltd.

Dapagliflozin Anhydrous Lactose Mixture 15.27mg
Tablet · Prescription medication
International Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
Shinil Pharmaceutical Co., Ltd.

Dapagliflozin Anhydrous Lactose Mixture 15.27mg
Tablet · Prescription medication
Sinil Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
Dongwha Pharmaceutical Co., Ltd.

Dapagliflozin Anhydrous Lactose Mixture 15.27mg
Tablet · Prescription medication
Donghwa Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
Albozen Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.